DDInter1873 DDInter1544
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Trimethobenzamide {u} (Compound) resembles {v} (Compound) Bevantolol
Trimethobenzamide {u} (Compound) resembles {v} (Compound) Cisapride
Trimethobenzamide {u} (Compound) upregulates {v} (Gene) HIST1H2BK
Trimethobenzamide {u} (Compound) is included by {v} (Pharmacologic Class) Emesis Suppression
Trimethobenzamide {u} (Compound) causes {v} (Side Effect) Disorientation
Trimethobenzamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Midazolam
Trimethobenzamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Trimethobenzamide {u} may lead to a major life threatening interaction when taken with {v} Dextropropoxyphene
Trimethobenzamide (Compound) resembles Bevantolol (Compound)
Trimethobenzamide (Compound) resembles Cisapride (Compound)
Trimethobenzamide (Compound) upregulates HIST1H2BK (Gene)
Trimethobenzamide (Compound) is included by Emesis Suppression (Pharmacologic Class)
Trimethobenzamide (Compound) causes Disorientation (Side Effect)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Midazolam
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Trimethobenzamide may lead to a major life threatening interaction when taken with Dextropropoxyphene